Amplified Sciences initiated patient enrollment for PanAMP, a multicenter clinical utility study designed to evaluate how its PanCystPro assay influences clinical decision-making for early pancreatic cancer detection. The study is positioned as a real-world evaluation of diagnostic utility rather than a purely analytic test validation. For industry observers, this type of study can support downstream adoption by addressing payer and clinician questions on how a biomarker changes management steps—who gets monitored, who proceeds to confirmatory workups, and what outcomes follow. If PanAMP demonstrates measurable decision changes consistent with clinical benefit, it would strengthen the case for scaling early-detection diagnostics in a notoriously difficult-to-treat cancer setting.